<DOC>
	<DOC>NCT02706899</DOC>
	<brief_summary>This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS).</brief_summary>
	<brief_title>Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS</brief_title>
	<detailed_description>In the phase 1 portion of the study, escalating doses of 33A will be evaluated in combination with azacitidine, and a dose of 33A will be selected to proceed to phase 2. The phase 2 portion of the study is randomized, double-blind and placebo-controlled; it is designed to compare the overall response rate (ORR) between 2 study arms.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Subjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO) 2008 classification. Previously untreated for Myelodysplastic Syndrome (MDS) Age ≥18 years of age. Eligible for therapy with azacitidine. Life expectancy of at least 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Adequate baseline laboratory parameters. Received prior treatment for MDS with lenalidomide or hypomethylating agents (HMAs). History of one of the following myeloproliferative neoplasms: essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Second malignancy currently requiring active therapy (except for hormonal/antihormonal treatment, eg, prostate or breast cancer).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibody-Drug Conjugate CD33 Antigen</keyword>
</DOC>